Hundreds of police officers and firefighters are expected to get the coronavirus vaccine in Montgomery County.
Disneyland, Universal Studios and other theme parks in California — as well as sports stadiums — have gotten the green light to reopen their gates once again after a long shutdown prompted by the ongoing COVID-19 pandemic.“ “With case rates and hospitalizations significantly lower, the arrival of three highly effective vaccines and targeted efforts aimed […]
Fifteen years after her death, Seattle science-fiction author Octavia E. Butler has joined an exclusive pantheon of space luminaries memorialized on Mars. Today NASA announced that the Red Planet locale where its Perseverance rover touched down last month is called Octavia E. Butler Landing, in honor of a Black author who emphasized diversity in tales of alternate realities and far-out futures. “Butler’s protagonists embody determination and inventiveness, making her a perfect fit for the Perseverance rover mission and its theme of overcoming challenges,” Kathryn Stack Morgan, deputy project scientist for Perseverance, said in a news release. “Butler inspired and influenced… Read More
(Bloomberg) -- Airline executives and directors sold $49.9 million of stock in February, the most in three years, as industry shares posted a record rally fueled by a widening vaccination effort.The top individual sellers were at Allegiant Travel Co. and Southwest Airlines Co., two leisure-focused carriers that are among analyst picks to benefit from a rebound in vacation travel as the coronavirus pandemic eases. Executives from Delta Air Lines Inc. and Mesa Air Group Inc. also sold significant holdings, according to data from InsiderInsights.com, which analyzes such transactions.The insider sales increased as investors bet that vaccine campaigns would gain steam and improve the prospects for a travel rebound. Airlines got hammered last year by an unprecedented drop in demand for flights. Continued stock gains are far from guaranteed this year, as the industry’s recovery remains shrouded in uncertainty and the slump in lucrative corporate and international trips is expected to drag on.The February surge in stock sales came after no airline insiders sold shares the previous month. An index of nine U.S. airlines jumped 30% in February, the most on record, led by a 45% advance for SkyWest Inc. Through Thursday, the stock gauge had rallied about 140% since hitting a seven-year low in May 2020.As if to underscore the uncertainty, however, the index plunged as much as 8.3% during the Friday trading session before paring losses to close with a fall of only 0.8%.Pay LimitsMajor carriers slashed jobs and cut executive pay because of the crisis, while Congress imposed compensation limits in exchange for tens of billions of dollars in aid.Bloomberg News surveyed insider transactions for the 11 largest publicly traded U.S. carriers. The data exclude April 2020, when Warren Buffett’s Berkshire Hathaway Inc. dumped its large stakes in the four biggest U.S. airlines.Last month, Allegiant Chief Executive Officer Maury Gallagher Jr. was the industry’s top seller, shedding 101,000 shares worth $21.5 million in 13 transactions. Last year, he sold shares worth $67.9 million. Gallagher still owns more than 13% of outstanding shares in Las Vegas-based Allegiant, which he co-founded in 1997.The company’s chief operating officer and chief financial officer also sold holdings of more than $1 million apiece. Allegiant declined to comment on executives’ personal decisions to sell shares, said spokeswoman Hilarie Grey. The transactions continued this month as Allegiant President John Redmond sold shares worth $6.1 million.Southwest’s insider sales made up 19% of the February total for airlines. President Tom Nealon collected at $2.98 million, while Chief Operating Officer Mike Van de Ven got $1.82 million and Chief Financial Officer Tammy Romo had $1.74 million. Restricted stock units paid to executives that vest in February carry “significant” taxes that aren’t fully covered by shares withheld for that purpose, Southwest said in regard to last month’s sales.Delta President Glen Hauenstein sold $2.63 million, while Mesa Air President Michael Lotz shed $1.79 million. Delta declined to comment.”Our window is open infrequently and we’ve been accumulating stock for a long time and took the opportunity to diversify holdings,” said Mesa CEO Jonathan Ornstein, who also sold nearly $915,000 in shares last month.Executives and directors at American Airlines Group Inc. and United Airlines Holdings Inc. sold no shares, according to available data.(Updates Allegiant president’s sale this month in ninth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Plus, she shares the recipe for her sour cream pound cake.
After the North Dakota House voted to expel a lawmaker accused of a long pattern of sexually harassing women at the Capitol, attention has turned to a policy that was intended to protect against harassment but may have actually made it harder to stop it. Legislative leaders vowed Friday to overhaul the policy crafted less than three years ago regarding workplace and sexual harassment at the Capitol, with an eye toward removing a requirement that eventually could make a victim’s identity public, which may have kept some women from coming forward. “Obviously, there is some grey areas that need to be filled in,” said Chet Pollert, the House Majority leader.
Convicted baby killer Cayce Williams has registered as a sex offender in a Chicago suburb after being released 24 years early from prison Thursday.
Borrowers and their parents and grandparents were among those who suffered when Navient violated a state consumer protection law, the court ruled.
Cardston, Alberta--(Newsfile Corp. - March 5, 2021) - American Creek Resources Ltd. (TSXV: AMK) ("American Creek") ("the Company") today announced that Sean Pownall is resigning from the American Creek Board of Directors effective at the close of business today. Mr. Pownall will remain on the Stinger Resources Inc. Board of Directors.Darren Blaney, CEO of American Creek stated: "We very much appreciate Sean's value and contribution to the American Creek board over the years. ...
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported today the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. The trial’s data has been reported to the U.S. Food and Drug Administration (“FDA”), the U.K.’s Medicines & Healthcare product Regulatory Agency (“MHRA”) and Health Canada (“HC”), and the Company is in discussions with each to determine the best path forward for approval of leronlimab for treatment of COVID-19 in critically ill population. A manuscript of the trial’s data is being prepared and will be submitted for publication in one or more major medical journals. Highlights from the trial’s data for this critically ill population include the following: Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo.Shortened time to recovery: The average length of hospital stay was reduced by 6 days for patients who received leronlimab with ”commonly used COVID-19 treatments,” also referred to as “Standard of Care” or “SoC,” compared to placebo patients who received SoC only, with a statistically significant p-value of 0.005.Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group. Given the size of this critically ill population relative to the trial’s size (62 out of 384 patients), the Company has concurrently filed an additional protocol with the FDA using the existing sites from its CD12 trial to quickly enroll patients in this population during the pendency of these ongoing regulatory discussions. The Company has continued to enroll patients (45) through the open-label arm of the CD12 trial, and is working with regulators here and abroad to expedite this process. Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, commented, “The CD12 trial results are very promising and leronlimab may be the only safe medication to help critically ill patients.” Scott A. Kelly, M.D., Chairman and Chief Medical Officer, noted, “We believe this further supports CCR5 as a therapeutic target for immunomodulation and the importance of the disruption of the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade of pro-inflammatory leukocytes and reversal of the cytokine storm in critical COVID-19 patients.” Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “Today, there are no approved drugs to effectively address the unmet medical need for critically ill COVID-19 patients. Our CD12 study demonstrates leronlimab is particularly effective in treating this patient population. We believe these results are the best results ever achieved for this population in a Phase 3 clinical trial. A recently approved IL-6 blocker used to treat severe to critical hospitalized COVID-19 patients requiring mechanical ventilation, reduced mortality by 2% compared to the placebo group. In contrast, leronlimab demonstrated a reduction of 24% in mortality compared to the SoC treated group, which is 12 times better in reducing all-cause mortality for critically ill COVID-19 patients. The Company is very excited about these results and is concurrently working with regulators here and abroad to expedite leronlimab’s approval to treat COVID-19.” About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed 11 clinical trials in over 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation by the FDA in May 2019. The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn was conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA granted orphan drug designation to leronlimab for the prevention of GvHD. Due to the lack of patients during the COVID-19 pandemic, the Company suspended its Phase 2 trial for acute GvHD. About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application ("BLA") for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of calendar year 2021. CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company's cash position, (ii) the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv) the Company's ability to enter into partnership or licensing arrangements with third parties, (v) the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company's ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company's clinical trials, (viii) the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. CONTACTSInvestors: Michael MulhollandOffice: 360.980.8524, ext. 102mmulholland@cytodyn.com
A nearly $2 billion plan to divert water and sediment from the Mississippi River to rebuild land in southeastern Louisiana — considered the cornerstone of the state's efforts to protect its rapidly eroding coast — has passed a major milestone with the publication of the long-awaited Army Corps of Engineers environmental impact study. The report issued late Thursday spells out the potential benefits of the plan projected to build thousands of acres of freshwater marshes on the western side of the Mississippi River that will help knock down storm surge in the New Orleans area to the north. The Mid-Barataria Sediment Diversion will essentially cut a hole into the levee around the town of Ironton, southeast of New Orleans, and channel part of the river's flow into Barataria Bay.
Tracy Morgan explained to Jimmy Fallon what happened when he mispronounced 'Soul' while presenting an award at this past weekend's Golden Globes.
Thousands say they are using drugs like LSD and MDMA to deal with emotional and other mental health issues
Dunkin' Donuts is (obviously) known for their sugary and delicious donuts, and in the past few years, their incredible coffee. But in a move to attract even more customers, Dunkin' recently got in on a trend that's been popular for a few years now: avocado toast!
Mar. 5—PRINCETON — A Mercer County resident is facing multiple felony charges including first-degree sexual assault and brandishing a deadly weapon after allegedly attacking a female individual that he knew. Brandon R.D. Green, 19, of Athens was arrested Wednesday and charged with first-degree sexual assault, assault during the commission of a felony, unlawful restraint, domestic battery and ...
Mar. 5—SPANISHBURG — Highway crews will need about two weeks to repair an undermined road running alongside Mercer County's Bluestone River, an engineer with the West Virginia Division of Highways said Thursday. Part of Route 19 near Spanishburg School collapsed suddenly Wednesday night, according to Joe Pack, administrator for District 10 of the state Division of Highways. "It would be north ...
President Joe Biden on Friday rounded out his White House staff with a top adviser who has advocated for breaking up Big Tech companies along with a host of new appointments focused on COVID-19, criminal justice and the U.S. economy. The White House announced six additional staffers to its National Economic Council, including Columbia University professor Tim Wu, who coined the term "net neutrality" and has warned against an economy dominated by a few giant firms. "I think breakups or undoing of mergers are actually called for more than we have appreciated in the last few decades," Wu has said previously about Big Tech companies.
Dony Garment Company, a subsidiary of Dony International Corporation - a leading Vietnamese garment manufacturer, has recently announced its new community face mask supply chains across the EU and US. FDA, CE Community Face Mask Manufacturer Announces More Supply Chains across EU/US - Nano-biotech, against SARS-CoV-2, Anti Coronavirus Dony Garment Company, a subsidiary of Dony International Corporation - a leading Vietnamese garment manufacturer, has recently announced its new community face mask supply chains across the EU and US. Dony Garment Company Dony Garment Company Ho Chi Minh City, Vietnam, March 05, 2021 (GLOBE NEWSWIRE) -- This came as a result of the company’s plans to beef up its reach and extend its supply chains across counties in Europe and America to ensure easy access to its washable and reusable premium antibacterial cloth mask. According to Mr. Pham Quang Anh, CEO of DONY Garment Company, the worldwide expansion of Dony’s supply chains is aimed at creating a better alternative to international buyers seeking new suppliers based in nations outside of China to purchase various lines products, especially face masks. “This year, we have found that many international buyers are seeking new suppliers based in nations outside of China to purchase many goods and products, including reusable cloth face mask and protective clothing (medical coverall disposable, surgical isolation gown),” said Mr. Pham. Mr. Pham further expresses his company’s readiness to welcome international customers, especially those based in the US, the EU and assure the highest quality supplies, affordable cost, and easy transport of products across the world; “At Dony Garment, we are proud to welcome international customers, especially those based in the US, the EU, and the Middle East market to discover our professional line of products which are manufactured in our factory in Vietnam, especially our new products for COVID-19. We guarantee our products are of the highest quality, at an affordable cost, and easy to transport across the world.” Dony's supply chains cut across the USA, France, Australia, Belgium, Singapore, Germany, Canada, Hong Kong, Macao Malaysia, South Africa, Finland, Greece, Denmark, Japan, United Kingdom, Italy, Spain, Netherlands, Switzerland, Poland, Sweden, Austria, Norway, Romania, Portugal, Saudi Arabia (KSA), Egypt, UAE, Qatar, Morocco, Kuwait, Oman, Jordan, Bahrain. The Dony Mask is a certified premium antibacterial cloth mask that is washable and reusable, yet provides 100% protection against virus and bacterial infections. The three-layer mask has secured certifications from CE, FDA and TUV Reach and has passed almost all of the most world's rigid safety standards. It is made from a three-ply, water-resistant and 99.9% antibacterial cloth to offer uncompromisable protection from COVID-19. “The Dony Mask offers unbelievable protection from COVID-19 and other viruses, and it is very comfortable to wear. We know health professionals are going to embrace this product because of the many benefits associated with it and because this mask is affordable,” Mr. Pham added. The outer layer of the mask features a strong water-resistant material that prevents droplets from clinging to the mask, hence, limit the possibility of getting infected by a viral infection. Its middle layer functions as a filter, while the inner layer provides the most anti-bacterial effects. It is safe, reliable, and highly comfortable to wear all through the day and with a unisex, one-size-fits-all, and breathable design and a variety of color options. “We also know how important it is that a face mask be comfortable,” Pham said. “So, we have designed our masks to be able to be worn for the whole day comfortably in any setting imaginable,” said Mr. Pham Quang Anh. Some of the unique features of Dony Mask include: Meet all the rigorous requirements for global export and use.Its strap could extend 270 percent of the original length, which reduces the discomfort for users when wearing the mask for a long time.Sustain anti-bacterial capability up to 99,9% even after 60 washes (no other masks reach this pinnacle yet). Equipped with three layers for maximum protection (Antimicrobial Finished). Take out packaging and wear without washing (Dony Mask sterilized with E.O gas technology used for Medical Supplies - E.O gas has the ability to penetrate the tiniest of pathways and destroy all kinds of bacteria and viruses).Super skin-friendly and tailored to even those with sensitive skin. Comfortable for prolonged use as it is odor-free, adjustable, breathable. No suffocation issues will be encountered, thus ideal for sports players.Filter dust particles and Fungi-proofing. Come in different colors that are currently in fashion.Resist dust, odor, and UV (The UV-resistance level of our face masks is 99.95%, which is equal to that of premium sunscreen lotions).Eco-friendly and Save over 85% vs. disposable mask. The Dony Garment Company provides distribution for business-to-business (B2B) purposes and even exclusive partnerships, and recently got a new Exclusive Distributor in Canada among other countries in the US and EU. They also offer corporate logo or label customization to suit any business need. “We try to cover every base when it comes to ensuring each of our business partners has complete trust in our company, our product, and our ability to deliver an amazing product at bulk prices,” Pham said. On the evening of 5th June 2020, Dony Garment Company and other Vietnamese enterprises have donated medical supplies to the US”s people. At the Ceremony of Offering Medical Materials to the United States, Dony presented 100,000 antibacterial gauze masks worth more than VND 10.5 billion. Overcoming many businesses that have signed up to give antibacterial masks, through testing, only Dony Mask has met the quality standards for use in the US. It's a big honor for Dony. Dony Mask is the only available reusable face mask that successfully passes through multiple quality checks, to be accepted for use in the U.S finally. Mr. Daniel Kritenbrink, U.S. Ambassador in Vietnam has extended his heartfelt gratitude and confirmed that Operation USA Organization which based in Los Angeles, USA will distribute these medical supplies to needed places such as California, New York, etc. About Dony Garment Company Established in 2009, the Dony Garment Company, a subsidiary of Dony International Corporation, is one of the largest manufacturers in Vietnam for making workwear, uniforms, and casual clothing. In 2020, DONY responded to the Covid-19 crisis by pivoting its activity to the manufacture of quality compliant PPE and exportation around the world including America, Europe, Australia, and Asia. To know more about Dony Mask and the company's supply chain policies, visit Dony Garment Company's official website at https://garment.dony.vn/profile-dony/. Or visit their YouTube channel: http://youtube.com/watch?v=fmcXNj569lA . Media contact: Dony Garment Company Henry Pham ~ +84985310123 This news has been published for the above source. Dony Garment Company [ID=17192] Disclaimer: The information does not constitute advice or an offer to buy. Any purchase made from this story is made at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling. The content publisher and its distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about. Attachments FDA, CE Community Face Mask Manufacturer Announces More Supply Chains across EU/US - Nano-biotech, against SARS-CoV-2, Anti Coronavirus Dony Garment Company
AT&T and three employees charged with allegedly disclosing 'material nonpublic information' to some analysts back in 2016, an allegation the company called 'meritless.'
Loans and grants will be distributed by the Rugby Football Union to community clubs.
Yahoo Home